Evidence map›Paper›PMID 39276048›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2024

[Assessment of baseline CCL19

M Zhu, B Wang, X Zhang, K Zhou, Z Miao, J Sun

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M ZhuClinical Medical College, Henan University of Science and Technology,Luoyang 471003, China.
B WangClinical Medical College, Henan University of Science and Technology,Luoyang 471003, China.
X ZhangClinical Medical College, Henan University of Science and Technology,Luoyang 471003, China.
K ZhouClinical Medical College, Henan University of Science and Technology,Luoyang 471003, China.
Z MiaoClinical Medical College, Henan University of Science and Technology,Luoyang 471003, China.
J SunCancer Hospital of First Affiliated Hospital, Henan University of Science and Technology,Luoyang 471003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the correlation of baseline CCL19

methodsWe retrospectively analyzed the data of patients with lung adenocarcinoma hospitalized at First Affiliated Hospital of Henan University of Science and Technology from January, 2020 to December, 2023, and collected tissue samples from 96 patients undergoing immunotherapy for assessing CCL19

resultsThe patients with partial or complete remission following immunotherapy had a significantly higher baseline CCL19

conclusionThe baseline CCL19

Indexed as

Adenocarcinoma of LungChemokine CCL19Dendritic CellsImmunotherapyLung NeoplasmsCD8-Positive T-LymphocytesFemaleGranzymesHumansMaleMiddle AgedRetrospective StudiesTumor MicroenvironmentCCL19 protein, humanChemokine CCL19GranzymesCCL19+ dendritic cellsCD8+ T cellsimmunotherapylung adenocarcinoma

Identifiers

PMID39276048
PMCPMC11378044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.